These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17377763)

  • 1. [How do medications used to treat urinary incontinence affect the cerebral function of the elderly?].
    Goepel M; Steinwachs KC
    Urologe A; 2007 Apr; 46(4):387-8, 390-2. PubMed ID: 17377763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactive bladder in the elderly: a guide to pharmacological management.
    Staskin DR
    Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.
    Pagoria D; O'Connor RC; Guralnick ML
    Curr Urol Rep; 2011 Oct; 12(5):351-7. PubMed ID: 21607875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic receptors in the bladder: from basic research to therapeutics.
    Hegde SS
    Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S80-7. PubMed ID: 16465186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticholinergics for overactive bladder: does subtype selectivity play a role?].
    Michel MC; Barendrecht MM; Oelke M
    Urologe A; 2006 Jul; 45(7):826-9. PubMed ID: 16767455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
    Kay GG; Abou-Donia MB; Messer WS; Murphy DG; Tsao JW; Ouslander JG
    J Am Geriatr Soc; 2005 Dec; 53(12):2195-201. PubMed ID: 16398909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral anticholinergics in overactive bladder].
    Madersbacher H
    Urologe A; 2006 Jul; 45(7):830-4. PubMed ID: 16791627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?
    MacDiarmid SA
    BJU Int; 2007 Jun; 99 Suppl 3():8-12. PubMed ID: 17488367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of overactive bladder in elderly and old people].
    Zellner M
    Urologe A; 2007 Apr; 46(4):382-6. PubMed ID: 17356833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevating our therapeutic expectations in overactive bladder.
    Sand PK
    J Am Acad Nurse Pract; 2004 Oct; 16(10 Suppl):8-11. PubMed ID: 15543927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study.
    Arana A; Margulis AV; McQuay LJ; Ziemiecki R; Bartsch JL; Rothman KJ; Franks B; D'Silva M; Appenteng K; Varas-Lorenzo C; Perez-Gutthann S
    Pharmacotherapy; 2018 Jun; 38(6):628-637. PubMed ID: 29723926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer agents for the management of overactive bladder.
    Epstein BJ; Gums JG; Molina E
    Am Fam Physician; 2006 Dec; 74(12):2061-8. PubMed ID: 17186712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.
    Kay GG; Ebinger U
    Int J Clin Pract; 2008 Nov; 62(11):1792-800. PubMed ID: 18699842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.
    Kay GG; Granville LJ
    Clin Ther; 2005 Jan; 27(1):127-38; quiz 139-40. PubMed ID: 15763613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?
    Gibson W; Athanasopoulos A; Goldman H; Madersbacher H; Newman D; Spinks J; Wyndaele JJ; Wagg A
    Int J Clin Pract; 2014 Sep; 68(9):1165-73. PubMed ID: 25196247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.